Half-year report · Q2

Period2024-01-01 → 2024-06-30
Filed2024-08-13
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥264m2024-01-01 → 2024-06-30StandaloneNet sales
Revenue¥682m2023-01-01 → 2023-12-31StandaloneNet sales (5-year summary)
Revenue¥359m2023-01-01 → 2023-06-30StandaloneNet sales
Operating income−¥581m2024-01-01 → 2024-06-30StandaloneOperating income
Operating income−¥659m2023-01-01 → 2023-06-30StandaloneOperating income
Ordinary income−¥563m2024-01-01 → 2024-06-30StandaloneOrdinary income
Ordinary income−¥1.2bn2023-01-01 → 2023-12-31StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥662m2023-01-01 → 2023-06-30StandaloneOrdinary income
Profit before tax−¥562m2024-01-01 → 2024-06-30StandaloneIncome before income taxes
Profit before tax−¥661m2023-01-01 → 2023-06-30StandaloneIncome before income taxes
Net income−¥564m2024-01-01 → 2024-06-30StandaloneProfit loss
Net income−¥1.2bn2023-01-01 → 2023-12-31StandaloneNet income loss (5-year summary)
Net income−¥664m2023-01-01 → 2023-06-30StandaloneProfit loss
Total assets¥1.6bnat 2024-06-30StandaloneAssets
Total assets¥1.8bnat 2023-12-31StandaloneAssets
Total assets¥1.7bnat 2023-06-30StandaloneTotal assets (5-year summary)
Total liabilities¥487mat 2024-06-30StandaloneLiabilities
Total liabilities¥594mat 2023-12-31StandaloneLiabilities
Net assets / equity¥1.1bnat 2024-06-30StandaloneNet assets
Net assets / equity¥1.2bnat 2023-12-31StandaloneNet assets
Net assets / equity¥1.1bnat 2023-06-30StandaloneNet assets (5-year summary)
Cash and deposits¥1.1bnat 2024-06-30StandaloneCash and deposits
Cash and deposits¥1.3bnat 2023-12-31StandaloneCash and deposits
Cash & equivalents¥1.1bnat 2024-06-30StandaloneCash and cash equivalents
Cash & equivalents¥1.3bnat 2023-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.2bnat 2023-06-30StandaloneCash and cash equivalents
Cash & equivalents¥1.7bnat 2022-12-31dStandaloneCash and cash equivalents
Operating cash flow−¥677m2024-01-01 → 2024-06-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.1bn2023-01-01 → 2023-12-31StandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥595m2023-01-01 → 2023-06-30StandaloneNet cash provided by used in operating activities
Investing cash flow¥173,0002023-01-01 → 2023-12-31StandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥82,0002023-01-01 → 2023-06-30StandaloneNet cash provided by used in investment activities
Financing cash flow¥455m2024-01-01 → 2024-06-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥667m2023-01-01 → 2023-12-31StandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥113m2023-01-01 → 2023-06-30StandaloneNet cash provided by used in financing activities
EPS (basic)¥-10.212024-01-01 → 2024-06-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-24.622023-01-01 → 2023-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-13.72023-01-01 → 2023-06-30StandaloneBasic earnings loss per share (5-year summary)
Equity ratio68.0%at 2024-06-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio65.1%at 2023-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio67.2%at 2023-06-30StandaloneEquity to asset ratio (5-year summary)
Shares issued56,387,000at 2024-06-30StandaloneTotal number of issued shares (5-year summary)
Shares issued52,640,200at 2023-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued48,503,800at 2023-06-30StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 16
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-06-30−¥269m
jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2024-01-01 → 2024-06-30−¥447m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue2024-01-01 → 2024-06-30¥264m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue external2024-01-01 → 2024-06-30¥264m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentsegment profit2024-01-01 → 2024-06-30¥135m
Total Of Reportable Segments And Otherssegment totalrevenue2024-01-01 → 2024-06-30¥264m
Total Of Reportable Segments And Otherssegment totalrevenue external2024-01-01 → 2024-06-30¥264m
Total Of Reportable Segments And Otherssegment totalsegment profit2024-01-01 → 2024-06-30−¥312m
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-06-30−¥266m
jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2023-01-01 → 2023-06-30−¥602m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue2023-01-01 → 2023-06-30¥359m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue external2023-01-01 → 2023-06-30¥359m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentsegment profit2023-01-01 → 2023-06-30¥209m
Total Of Reportable Segments And Otherssegment totalrevenue2023-01-01 → 2023-06-30¥359m
Total Of Reportable Segments And Otherssegment totalrevenue external2023-01-01 → 2023-06-30¥359m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-01-01 → 2023-06-30−¥393m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 447
ItemContextValueUnit
Increase decrease in notes and accounts payable trade ope cfCurrentYTDDuration_NonConsolidatedMember-14720000JPY
Increase decrease in accounts payable other ope cfPrior1YTDDuration_NonConsolidatedMember710000JPY
Increase decrease in accounts payable other ope cfCurrentYTDDuration_NonConsolidatedMember-53467000JPY
Increase decrease in accrued expenses ope cfPrior1YTDDuration_NonConsolidatedMember1030000JPY
Increase decrease in accrued expenses ope cfCurrentYTDDuration_NonConsolidatedMember-1218000JPY
Other net ope cfPrior1YTDDuration_NonConsolidatedMember8568000JPY
Other net ope cfCurrentYTDDuration_NonConsolidatedMember-11621000JPY
Subtotal ope cfPrior1YTDDuration_NonConsolidatedMember-589373000JPY
Subtotal ope cfCurrentYTDDuration_NonConsolidatedMember-671113000JPY
Interest income received ope cfPrior1YTDDuration_NonConsolidatedMember8000JPY
Interest income received ope cfCurrentYTDDuration_NonConsolidatedMember17000JPY
Interest expenses paid ope cf fin cfPrior1YTDDuration_NonConsolidatedMember-910000JPY
Interest expenses paid ope cf fin cfCurrentYTDDuration_NonConsolidatedMember-1282000JPY
Income taxes paid ope cfPrior1YTDDuration_NonConsolidatedMember-5010000JPY
Income taxes paid ope cfCurrentYTDDuration_NonConsolidatedMember-5010000JPY
Income taxes refund ope cfPrior1YTDDuration_NonConsolidatedMember3000JPY
Income taxes refund ope cfCurrentYTDDuration_NonConsolidatedMember-JPY
Net cash provided by used in operating activitiesPrior1YTDDuration_NonConsolidatedMember-595281000JPY
Net cash provided by used in operating activitiesCurrentYTDDuration_NonConsolidatedMember-677388000JPY
Proceeds from sales of property plant and equipment inv cfPrior1YTDDuration_NonConsolidatedMember82000JPY
Proceeds from sales of property plant and equipment inv cfCurrentYTDDuration_NonConsolidatedMember-JPY
Net cash provided by used in investment activitiesPrior1YTDDuration_NonConsolidatedMember82000JPY
Net cash provided by used in investment activitiesCurrentYTDDuration_NonConsolidatedMember-JPY
Increase in short term loans payable fin cfPrior1YTDDuration_NonConsolidatedMember130800000JPY
Increase in short term loans payable fin cfCurrentYTDDuration_NonConsolidatedMember22600000JPY
Decrease in short term loans payable fin cfPrior1YTDDuration_NonConsolidatedMember-16500000JPY
Decrease in short term loans payable fin cfCurrentYTDDuration_NonConsolidatedMember-21500000JPY
Proceeds from issuance of common stock fin cfPrior1YTDDuration_NonConsolidatedMember-JPY
Proceeds from issuance of common stock fin cfCurrentYTDDuration_NonConsolidatedMember454390000JPY
Payments for issuance of common stock fin cfPrior1YTDDuration_NonConsolidatedMember-940000JPY
Payments for issuance of common stock fin cfCurrentYTDDuration_NonConsolidatedMember-JPY
Other net fin cfPrior1YTDDuration_NonConsolidatedMember-0JPY
Other net fin cfCurrentYTDDuration_NonConsolidatedMember-JPY
Net cash provided by used in financing activitiesPrior1YTDDuration_NonConsolidatedMember113359000JPY
Net cash provided by used in financing activitiesCurrentYTDDuration_NonConsolidatedMember455490000JPY
Net increase decrease in cash and cash equivalentsPrior1YTDDuration_NonConsolidatedMember-481839000JPY
Net increase decrease in cash and cash equivalentsCurrentYTDDuration_NonConsolidatedMember-221898000JPY
Cash and cash equivalentsPrior2YearInstant_NonConsolidatedMember1727270000JPY
Cash and cash equivalentsPrior1YearInstant_NonConsolidatedMember1325554000JPY
Cash and cash equivalentsPrior1QuarterInstant_NonConsolidatedMember1245431000JPY
Cash and cash equivalentsCurrentQuarterInstant_NonConsolidatedMember1103656000JPY
Raw materialsPrior1YearInstant_NonConsolidatedMember62463000JPY
Raw materialsCurrentQuarterInstant_NonConsolidatedMember47046000JPY
Work in processPrior1YearInstant_NonConsolidatedMember1644000JPY
Work in processCurrentQuarterInstant_NonConsolidatedMember5397000JPY
Revenues from external customersPrior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember-JPY
Revenues from external customersPrior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoverySupportReportableSegmentsMember358889000JPY
Revenues from external customersPrior1YTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember358889000JPY
Revenues from external customersPrior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember-JPY
Revenues from external customersPrior1YTDDuration_NonConsolidatedMember358889000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identitynon_consolidated 2023-12-31pass
balance sheet identitynon_consolidated 2024-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · net assetsnon_consolidated 2024-06-30pass
statement vs summary · operating cash flownon_consolidated 2023-01-01/2023-06-30pass
statement vs summary · operating cash flownon_consolidated 2024-01-01/2024-06-30pass
statement vs summary · revenuenon_consolidated 2023-01-01/2023-06-30pass
statement vs summary · revenuenon_consolidated 2024-01-01/2024-06-30pass
statement vs summary · total assetsnon_consolidated 2023-12-31pass
statement vs summary · total assetsnon_consolidated 2024-06-30pass